Renal injury, abnormal vitamin D metabolism and bone homeostasis in aged rats with insulin resistance or type 2 diabetes mellitus

Journal of Investigative Medicine

Volumn 56, Issue 6, 2008, Pages 872-877

  Huang, Chang Quan ^a   Dong, Bi Rong ^a   Xiao, Qian ^a   He, Ping ^a   Ding, Qun Fang ^a   Lu, Zhen Chan ^a   Peng, Xiao Dong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

VITAMIN D;

AGING; ANIMAL; ARTICLE; BONE; BONE DENSITY; HOMEOSTASIS; INJURY; INSULIN RESISTANCE; KIDNEY; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; RAT; WISTAR RAT;

AGING; ANIMALS; BONE AND BONES; BONE DENSITY; DIABETES MELLITUS, TYPE 2; HOMEOSTASIS; INSULIN RESISTANCE; KIDNEY; MALE; RATS; RATS, WISTAR; VITAMIN D;

EID: 53449090994     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/jim.0b013e31817c4270     Document Type: Article

References (41)

1. 3 1alpha-hydroxylase and vitamin D synthesis. Science. 1997;277:1827-1830.
2. Ohyama Y, Yamasaki T. Eight cytochrome P450s catalyze vitamin D metabolism. Front Biosci. 2004;9:3007-3018.
3. 3-1alpha-hydroxylase along the nephron: new insights into renal vitamin D metabolism. Curr Opin Nephrol Hypertens. 2000;9:17-22.
4. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 2006;69:33-43.
5. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289:F8-F28.
6. Miller WL, Portale AA. Vitamin D biosynthesis and vitamin D 1 alpha-hydroxylase deficiency. Endocr Dev. 2003;6:156-174.
7. Okano T. Vitamin D, K and bone mineral density. Clin Calcium. 2005;15:1489-1494.
8. Ishimura E, Tsuchida T, Hirowatari K, et al. Annual change in bone mineral density in predialysis patients with chronic renal failure: significance of a decrease in serum 1,25-dihydroxy-vitamin D. J Bone Miner Metab. 2007;25: 74-79.
9. 3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration. Nephron. 1995;71:254-283.
10. Kasper DL, Harrison TR. Glomerular diseases. In: Harrison's Principles of Internal Medicine. 16th ed. New York: McGraw-Hill; 2005:1688-1689.
11. Toto Robert D. Appropriate drug therapy for improving outcomes in diabetic nephropathy. Curr Diab Rep. 2002;2: 545-552.
12. Whaley-Connell A, Pavey BS, et al. Obesity and insulin resistance as risk factors for chronic kidney disease. J Cardiometab Syndr. 2006;1(3):209-214; quiz 215-6.
13. Sit D, Kadiroglu AK, Kayabasi H, et al. The prevalence of insulin resistance in nondiabetic nonobese patients with chronic kidney disease. Adv Ther. 2006 Nov-Dec;23: 988-998.
14. Abrass CK. Overview: obesity: what does it have to do with kidney disease? J Am Soc Nephrol. 2004;15(11): 2768-2772.
15. Fliser D, Pacini G, Engelleiter R, et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int. 1998;53:1343-1347.
16. 3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract. 1995;27:181-188.
17. Pietschmann P, Schernthaner G, Woloszczuk W. Serum osteocalcin levels in diabetes mellitus: analysis of the type of diabetes and microvascular complications. Diabetologia. 1988;31:892-895.
18. Isaia G, Giorgino R, Adami S. High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care. 2001;24:1496.
19. Boucher BJ, Mannan N, Noonan K, et al. Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. Diabetologia. 1995;38:1239-1245.
20. Gloth FM, Gundberg CM, Hollis BW, et al. Vitamin D deficiency in homebound elderly persons. JAMA. 1995; 274:1683-1686.
21. Chung YS, Lee MD, Lee SK, et al. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab. 2000;85:1137-1142.
22. Gregorio F, Cristallini S, Santeusanio F, et al. Osteopenia associated with non-insulin-dependent diabetes mellitus: what are the causes? Diabetes Res Clin Pract. 1994;23: 43-54.
23. Nakashima A, Nakashima R, Ito T, et al. Title HMG-CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus. Diabet Med. 2004;21:1020-1024.
24. Takizawa M, Kameyama K, Maruyama M, et al. Loss in type 2 diabetes mellitus-diabetic osteopenia. Nippon Rinsho. 2003;61:287-291.
25. Blaedel WJ, Uhl JM. Nature of materials in serum that interfere in the glucose oxidase-peroxidase-O-dianisidine method for glucose, and their mode of action. Clin Chem. 1975;21:119-124.
26. Straczkowski M, Stepiec A, Kowalska I, et al. Comparison of simple indices of insulin sensitivity using the eugly-cemic hyperinsulinemic clamp technique. Med Sci Monit. 2004;10:CR480YCR484.
27. Watts GF, Albano JD, Bennett JE, et al. Assessment of new radioimmunoassay kit for determining urinary albumin at low concentrations: comparison with radial immunodiffusion. J Clin Patho. 1986;39:1151-1154.
28. Lilley J, Walters BG, Heath DA, et al. In vivo and in vitro precision for bone density measured by dual-energy X-ray absorption. Osteoporos Int. 1991;1:141-146.
29. Broholm B, Podenphant J, Biering-Sorensen F. The course of bone mineral density and biochemical markers of bone turnover in early postmenopausal spinal cord-lesioned females. Spinal Cord. 2005;43:674-677.
30. Spencer EM, Khalil M, Tobiassen O. Experimental diabetes in the rat causes an insulin-reversible decrease in renal 25-hydroxyvitamin D3-1 alpha-hydroxylase activity. Endocrinology. 1980;107:300-305
31. Hough S, Fausto A, Sonn Y, et al. Vitamin D metabolism in the chronic streptozotocin-induced diabetic rat. Endocrinology. 1983;113:790-796.
32. 3), 25 hydroxy vitamin D (25(OH)D) and parathormone levels in diabetic retinopathy. Clin Biochem. 2000;33:47-51.
33. Parvanova AI, Trevisan R, Iliev IP, et al. Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion Diabetes. 2006;55: 1456-1462.
34. Hoehner CM, Greenlund KJ, Rith-Najarian S, et al. Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol. 2002;13: 1626-1634.
35. Kawano K, Hirashima T, Mori S, et al. Spontaneous longterm hyperglycemic rat with diabetic complications: Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes. 1992;41:1422-1428.
36. De Cosmo S, Minenna A, Ludovico O, et al. Increased urinary albumin excretion, insulin resistance and related cardiovascular risk factors in patients with type 2 diabetes: evidence of a sex-specific association. Diabetes Care. 2005;28:910-915.
37. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 1998;352:213-219.
38. Yaqoob M, McClelland P, Patrick AW, et al. Tubulopathy with macroalbuminuria due to diabetic nephropathy and primary glomerulonephritis. Kidney Int Suppl. 1994;47: 101-104.
39. Yaqoob M, McClelland P, Patrick AW, et al. Evidence of oxidant injury and tubular damage in early diabetic nephropathy. QJM. 1994;87:601-607.
40. Karkkainen M, Tahtela R, Laitinen K, et al. Bone mass and markers of bone and calcium metabolism in post-menopausal women treated with 1,25-dihydroxyvitamin D (Calcitriol) for four years. Calcif Tissue Int. 2000;67: 122-127.
41. Tsuruoka S, Wakaumi M, Yamamoto H, et al. Chron-opharmacology of oxacalcitriol in rat model of osteoporosis. Eur J Pharmacol. 2004;19;488:239-245.